- Home
- DXCM vs BIIB Comparison
DXCM vs BIIB Comparison
Compare DXCM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- BIIB
- Stock Information
- Founded
- DXCM 1999
- BIIB 1978
- Country
- DXCM United States
- BIIB United States
- Employees
- DXCM N/A
- BIIB N/A
- Industry
- DXCM Medical/Dental Instruments
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DXCM Health Care
- BIIB Health Care
- Exchange
- DXCM Nasdaq
- BIIB Nasdaq
- Market Cap
- DXCM 28.0B
- BIIB 25.1B
- IPO Year
- DXCM 2005
- BIIB 1991
- Fundamental
- Price
- DXCM $79.31
- BIIB $164.23
- Analyst Decision
- DXCM Buy
- BIIB Buy
- Analyst Count
- DXCM 17
- BIIB 25
- Target Price
- DXCM $101.29
- BIIB $258.57
- AVG Volume (30 Days)
- DXCM 4.0M
- BIIB 1.7M
- Earning Date
- DXCM 10-24-2024
- BIIB 10-30-2024
- Dividend Yield
- DXCM N/A
- BIIB N/A
- EPS Growth
- DXCM 83.21
- BIIB 10.05
- EPS
- DXCM 1.67
- BIIB 11.06
- Revenue
- DXCM $3,954,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- DXCM $13.10
- BIIB N/A
- Revenue Next Year
- DXCM $14.79
- BIIB N/A
- P/E Ratio
- DXCM $47.58
- BIIB $14.85
- Revenue Growth
- DXCM 16.19
- BIIB N/A
- 52 Week Low
- DXCM $62.34
- BIIB $153.62
- 52 Week High
- DXCM $142.00
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- DXCM 66.81
- BIIB 42.84
- Support Level
- DXCM $72.51
- BIIB $158.44
- Resistance Level
- DXCM $79.38
- BIIB $160.63
- Average True Range (ATR)
- DXCM 2.87
- BIIB 4.14
- MACD
- DXCM 0.49
- BIIB 0.94
- Stochastic Oscillator
- DXCM 92.05
- BIIB 47.71
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.